Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Elke Tatjana Aristizabal Prada"'
Autor:
Svenja Nölting, Jakob Rentsch, Helma Freitag, Katharina Detjen, Franziska Briest, Markus Möbs, Victoria Weissmann, Britta Siegmund, Christoph J Auernhammer, Elke Tatjana Aristizabal Prada, Michael Lauseker, Ashley Grossman, Samantha Exner, Christian Fischer, Carsten Grötzinger, Jörg Schrader, Patricia Grabowski, GERMAN NET-Z study group
Publikováno v:
PLoS ONE, Vol 12, Iss 8, p e0182852 (2017)
BACKGROUND/AIMS:The therapeutic options for metastatic neuroendocrine tumors (NETs) are limited. As PI3K signaling is often activated in NETs, we have assessed the effects of selective PI3Kp110α inhibition by the novel agent BYL719 on cell viability
Externí odkaz:
https://doaj.org/article/d90eb6998c164c8c907816964c638484
Autor:
Elke Tatjana Aristizabal Prada, Michael Orth, Svenja Nölting, Gerald Spöttl, Julian Maurer, Christoph Auernhammer
Publikováno v:
PLoS ONE, Vol 12, Iss 5, p e0178375 (2017)
Modulation of the redox system in cancer cells has been considered a promising target for anti-cancer therapy. The novel MTH1 inhibitor TH588 proved tremendous potential in terms of cancer cell eradication, yet its specificity has been questioned by
Externí odkaz:
https://doaj.org/article/99520bd6ddeb4f24984f01bf1bf5aac3
Autor:
Svenja Nölting, Julian Maurer, Gerald Spöttl, Elke Tatjana Aristizabal Prada, Clemens Reuther, Karen Young, Márta Korbonits, Burkhard Göke, Ashley Grossman, Christoph J Auernhammer
Publikováno v:
PLoS ONE, Vol 10, Iss 12, p e0143830 (2015)
The mTORC1-inhibitor everolimus shows limited efficacy in treating patients with gastro-entero-pancreatic or pulmonary neuroendocrine tumors (NETs), and poor outcome in patients with malignant pheochromocytoma or hepatic carcinoma. We speculated that
Externí odkaz:
https://doaj.org/article/7ceee008dd6a4c06a10157da84b0f126
Autor:
Yuhong Yang, Tracy Ann Williams, Celso E. Gomez-Sanchez, Diana Jaquin, Felix Beuschlein, Lucie S. Meyer, Elke Tatjana Aristizabal Prada, Martin Reincke, Holger Schneider, Thomas Knösel
Publikováno v:
Hypertension
Aldosterone-producing adenomas with somatic mutations in the KCNJ5 G-protein–coupled inwardly rectifying potassium channel are a cause of primary aldosteronism. These mutations drive aldosterone excess, but their role in cell growth is undefined. O
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5eeac8e934cbf8695bab9c0fdb05cdd
https://doi.org/10.1161/hypertensionaha.119.13476
https://doi.org/10.1161/hypertensionaha.119.13476
Autor:
Svenja Nölting, Gerald Spoettl, Julian Maurer, Elke Tatjana Aristizabal Prada, Christoph J. Auernhammer
Publikováno v:
Neuroendocrinology. 106:58-73
Background/Aim: Cyclin-dependent kinases (CDKs) are crucial for cell cycle regulation, and alterations in the cell cycle are often observed in human cancer. CDK4/6 in particular orchestrates G1 phase progression and the G1/S transition. Here, we inve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99a09a43930f17efb313517ed431eeb3
https://doi.org/10.1159/000463386
https://doi.org/10.1159/000463386
Autor:
Svenja Nölting, Judith Goncalves, Judith Favier, Gerald Spöttl, Petra Rank, Barbara Klink, Michael Lauseker, Felix Beuschlein, German Rubinstein, Graeme Eisenhofer, Stefan R. Bornstein, Julian Maurer, Maria Fankhauser, M. Orth, Nicole Bechmann, Thomas Knösel, Doreen William, Laura Gieldon, Christoph J. Auernhammer, Martin Fassnacht, Karel Pacak, Elke Tatjana Aristizabal Prada, Ashley B. Grossman, Christine Spitzweg, Christian G. Ziegler, Martin Reincke
There are no officially approved therapies for metastatic pheochromocytomas apart from ultratrace 131I-metaiodbenzylguanidine therapy, which is approved only in the United States. We have, therefore, investigated the antitumor potential of molecular-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d188663d582d0ef44aaa693aca47d672
https://doi.org/10.5167/uzh-173847
https://doi.org/10.5167/uzh-173847
Autor:
Ensar Halilovic, Clemens Reuther, Gerald Spöttl, Elke Tatjana Aristizabal Prada, Jens Wuerthner, Stefanie Hahner, Svenja Nölting, Julian Maurer, Christoph J. Auernhammer, Vera Heinzle, Sabine Herterich, Sébastien Jeay
Publikováno v:
Neuroendocrinology. 106:1-19
Background/Aims: The tumor suppressor p53 is depleted in many tumor cells by the E3 ubiquitin ligase mouse double minute 2 homolog (MDM2) through MDM2/p53 interaction. A novel target for inhibiting p53 degradation and for causing reexpression of p53w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ddc2771da1365a01d7f6cddf74bc98b
https://doi.org/10.1159/000453369
https://doi.org/10.1159/000453369
Autor:
Felix Beuschlein, Eva J. Koziolek, Gerald Spöttl, Christoph Auernhammer, Karel Pacak, Elke Tatjana Aristizabal Prada, Julian Maurer, Michael Lauseker, Jörg Schrader, Ashley Grossman, Svenja Nölting
Publikováno v:
Endocr Relat Cancer
Pancreatic neuroendocrine tumors (panNETs) are often inoperable at diagnosis. The mTORC1 inhibitor everolimus has been approved for the treatment of advanced NETs. However, the regular development of resistance to everolimus limits its clinical effic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::728fdb18d30d105357bedaf5b3fdb33f
https://www.zora.uzh.ch/id/eprint/152272/
https://www.zora.uzh.ch/id/eprint/152272/
Publikováno v:
Endocrine Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e8bda06d60171b10d3658948d04665ce
https://doi.org/10.1530/endoabs.56.p53
https://doi.org/10.1530/endoabs.56.p53
Autor:
Felix Beuschlein, Nina Schmidt, Thomas Knösel, Günter K. Stalla, Svenja Nölting, Martin K. Angele, Gerald Spöttl, Rainer Blaser, Vera Heinzle, Klaus A. Kuhn, Elke Tatjana Aristizabal Prada, Christoph J. Auernhammer, Julian Maurer, Christine Spitzweg
Publikováno v:
Endocrine-related cancer. 25(5)
Tropomyosin receptor kinase (Trk) inhibitors are investigated as a novel targeted therapy in various cancers. We investigated thein vitroeffects of the pan-Trk inhibitor GNF-5837 in human neuroendocrine tumor (NET) cells. The human neuroendocrine pan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d71f04e37d0ddaa3caa2e97ec59f685
https://pubmed.ncbi.nlm.nih.gov/29563190
https://pubmed.ncbi.nlm.nih.gov/29563190